Research programme: clofarabine - Heidelberg Pharma

Drug Profile

Research programme: clofarabine - Heidelberg Pharma

Alternative Names: Clofarabine-EPD; EPD-clofarabine; HDP 15.0022

Latest Information Update: 19 Apr 2011

Price : $50

At a glance

  • Originator Heidelberg Pharma
  • Class Antineoplastics; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 28 Feb 2011 Heidelberg Pharma has been acquired by Wilex
  • 15 Nov 2010 Suspended - Preclinical for Solid tumours in Germany (PO) before November 2010
  • 22 Apr 2009 Preclinical trials in Solid tumours in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top